Apellis Pharmaceuticals, Inc. (APLS) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Cedric Francois.
APLS を有する IPO日 2017-11-09, 705 名の正社員, に上場 NASDAQ Global Select, 時価総額 $5.22B.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. The company's lead product, pegcetacoplan, is in Phase III clinical trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, with the approved product EMPAVELI addressing multiple rare hematologic, nephrologic, and neurologic indications. Apellis maintains a robust pipeline including APL-2006, a bispecific C3 and VEGF inhibitor, and APL-1030, a C3 inhibitor for neurodegenerative diseases, supported by strategic collaborations with Swedish Orphan Biovitrum AB and Beam Therapeutics. Founded in 2009 and headquartered in Waltham, Massachusetts, the company is advancing complement-inhibition science across multiple therapeutic areas with significant unmet medical needs.
